Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417
Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium ® and Detalliptinium ®, two ellipticine derivati...
Gespeichert in:
Veröffentlicht in: | Biochemical pharmacology 1989-07, Vol.38 (13), p.2077-2086 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2086 |
---|---|
container_issue | 13 |
container_start_page | 2077 |
container_title | Biochemical pharmacology |
container_volume | 38 |
creator | Multon, Eric Riou, Jean-François LeFevre, Dominique Ahomadegbe, Jean-Charles Riou, Guy |
description | Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium
® and Detalliptinium
®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest
in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The
in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human
c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from
m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium
® presents a strong cytotoxic activity
in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the
in vivo DNA cleavage activity of Celiptium
® and Detalliptinium
® on a human SCLC cell line, NCI N417, comparatively to that obtained with
m-AMSA. The respective IC
50 on cell growth are 9, 8 and 1 μM for Celiptium
®, Detalliptinium
® and
m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium
® and Detalliptinium
® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than
m-AMSA in inducing DNA strand breaks. Analysis of
in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With
m-AMSA,
c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium
® and Detalliptinium
® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than
m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by
in vitro and isolated nuclei experiments. |
doi_str_mv | 10.1016/0006-2952(89)90060-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79046978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006295289900609</els_id><sourcerecordid>79046978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</originalsourceid><addsrcrecordid>eNp9kE1vEzEQhi0EKmnhH4DkA0JwWLBjrz8ulapSIFJVLuVsTewxNdqPYO9Gyr_HS6IcOdnj95nR-CHkDWefOOPqM2NMNWvbrj8Y-9HWgjX2GVlxo0V9VuY5WZ2Rl-SylN9LaRS_IBfrVkpuxIqkx3E3pjL2mKEg3WyaHkOCCQP98nBDfYewh19IwU9pn6YDTUOYfU23B4pdl3ZT8mnAQseBTk9In-Ye6m3ux0x9BWhXU_oguX5FXkToCr4-nVfk59e7x9vvzf2Pb5vbm_vGC6OmJkYJRkihxLb-RMsYQENoY4ueSdDRhohCqtYHtY3MywAevZLAI48ClRBX5P1x7i6Pf2Ysk-tTWVaBAce5OG2ZVFabCsoj6PNYSsbodjn1kA-OM7cYdosvt-hzxrp_hp2tbW9P8-dtdXVuOimt-btTDsVDFzMMPpUzplptlWYVuz5iWF3sE2ZXfMKhqk0Z_eTCmP6_x1_U4Zgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79046978</pqid></control><display><type>article</type><title>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Multon, Eric ; Riou, Jean-François ; LeFevre, Dominique ; Ahomadegbe, Jean-Charles ; Riou, Guy</creator><creatorcontrib>Multon, Eric ; Riou, Jean-François ; LeFevre, Dominique ; Ahomadegbe, Jean-Charles ; Riou, Guy</creatorcontrib><description>Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium
® and Detalliptinium
®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest
in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The
in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human
c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from
m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium
® presents a strong cytotoxic activity
in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the
in vivo DNA cleavage activity of Celiptium
® and Detalliptinium
® on a human SCLC cell line, NCI N417, comparatively to that obtained with
m-AMSA. The respective IC
50 on cell growth are 9, 8 and 1 μM for Celiptium
®, Detalliptinium
® and
m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium
® and Detalliptinium
® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than
m-AMSA in inducing DNA strand breaks. Analysis of
in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With
m-AMSA,
c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium
® and Detalliptinium
® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than
m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by
in vitro and isolated nuclei experiments.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/0006-2952(89)90060-9</identifier><identifier>PMID: 2544183</identifier><identifier>CODEN: BCPCA6</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Alkaloids - pharmacology ; Amsacrine - pharmacology ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Carcinoma, Small Cell ; Cell Division - drug effects ; Cell Line ; DNA - drug effects ; DNA Damage ; DNA Topoisomerases, Type II - metabolism ; Ellipticines - pharmacology ; General aspects ; Humans ; Lung Neoplasms ; Medical sciences ; Pharmacology. Drug treatments ; Tumor Cells, Cultured - drug effects ; Tumor Cells, Cultured - enzymology</subject><ispartof>Biochemical pharmacology, 1989-07, Vol.38 (13), p.2077-2086</ispartof><rights>1989</rights><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</citedby><cites>FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0006295289900609$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6579670$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2544183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Multon, Eric</creatorcontrib><creatorcontrib>Riou, Jean-François</creatorcontrib><creatorcontrib>LeFevre, Dominique</creatorcontrib><creatorcontrib>Ahomadegbe, Jean-Charles</creatorcontrib><creatorcontrib>Riou, Guy</creatorcontrib><title>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium
® and Detalliptinium
®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest
in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The
in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human
c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from
m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium
® presents a strong cytotoxic activity
in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the
in vivo DNA cleavage activity of Celiptium
® and Detalliptinium
® on a human SCLC cell line, NCI N417, comparatively to that obtained with
m-AMSA. The respective IC
50 on cell growth are 9, 8 and 1 μM for Celiptium
®, Detalliptinium
® and
m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium
® and Detalliptinium
® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than
m-AMSA in inducing DNA strand breaks. Analysis of
in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With
m-AMSA,
c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium
® and Detalliptinium
® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than
m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by
in vitro and isolated nuclei experiments.</description><subject>Alkaloids - pharmacology</subject><subject>Amsacrine - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Small Cell</subject><subject>Cell Division - drug effects</subject><subject>Cell Line</subject><subject>DNA - drug effects</subject><subject>DNA Damage</subject><subject>DNA Topoisomerases, Type II - metabolism</subject><subject>Ellipticines - pharmacology</subject><subject>General aspects</subject><subject>Humans</subject><subject>Lung Neoplasms</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Cells, Cultured - drug effects</subject><subject>Tumor Cells, Cultured - enzymology</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1vEzEQhi0EKmnhH4DkA0JwWLBjrz8ulapSIFJVLuVsTewxNdqPYO9Gyr_HS6IcOdnj95nR-CHkDWefOOPqM2NMNWvbrj8Y-9HWgjX2GVlxo0V9VuY5WZ2Rl-SylN9LaRS_IBfrVkpuxIqkx3E3pjL2mKEg3WyaHkOCCQP98nBDfYewh19IwU9pn6YDTUOYfU23B4pdl3ZT8mnAQseBTk9In-Ye6m3ux0x9BWhXU_oguX5FXkToCr4-nVfk59e7x9vvzf2Pb5vbm_vGC6OmJkYJRkihxLb-RMsYQENoY4ueSdDRhohCqtYHtY3MywAevZLAI48ClRBX5P1x7i6Pf2Ysk-tTWVaBAce5OG2ZVFabCsoj6PNYSsbodjn1kA-OM7cYdosvt-hzxrp_hp2tbW9P8-dtdXVuOimt-btTDsVDFzMMPpUzplptlWYVuz5iWF3sE2ZXfMKhqk0Z_eTCmP6_x1_U4Zgg</recordid><startdate>19890701</startdate><enddate>19890701</enddate><creator>Multon, Eric</creator><creator>Riou, Jean-François</creator><creator>LeFevre, Dominique</creator><creator>Ahomadegbe, Jean-Charles</creator><creator>Riou, Guy</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19890701</creationdate><title>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</title><author>Multon, Eric ; Riou, Jean-François ; LeFevre, Dominique ; Ahomadegbe, Jean-Charles ; Riou, Guy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Alkaloids - pharmacology</topic><topic>Amsacrine - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Small Cell</topic><topic>Cell Division - drug effects</topic><topic>Cell Line</topic><topic>DNA - drug effects</topic><topic>DNA Damage</topic><topic>DNA Topoisomerases, Type II - metabolism</topic><topic>Ellipticines - pharmacology</topic><topic>General aspects</topic><topic>Humans</topic><topic>Lung Neoplasms</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Cells, Cultured - drug effects</topic><topic>Tumor Cells, Cultured - enzymology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Multon, Eric</creatorcontrib><creatorcontrib>Riou, Jean-François</creatorcontrib><creatorcontrib>LeFevre, Dominique</creatorcontrib><creatorcontrib>Ahomadegbe, Jean-Charles</creatorcontrib><creatorcontrib>Riou, Guy</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Multon, Eric</au><au>Riou, Jean-François</au><au>LeFevre, Dominique</au><au>Ahomadegbe, Jean-Charles</au><au>Riou, Guy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>1989-07-01</date><risdate>1989</risdate><volume>38</volume><issue>13</issue><spage>2077</spage><epage>2086</epage><pages>2077-2086</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><coden>BCPCA6</coden><abstract>Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium
® and Detalliptinium
®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest
in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The
in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human
c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from
m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium
® presents a strong cytotoxic activity
in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the
in vivo DNA cleavage activity of Celiptium
® and Detalliptinium
® on a human SCLC cell line, NCI N417, comparatively to that obtained with
m-AMSA. The respective IC
50 on cell growth are 9, 8 and 1 μM for Celiptium
®, Detalliptinium
® and
m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium
® and Detalliptinium
® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than
m-AMSA in inducing DNA strand breaks. Analysis of
in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With
m-AMSA,
c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium
® and Detalliptinium
® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than
m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by
in vitro and isolated nuclei experiments.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2544183</pmid><doi>10.1016/0006-2952(89)90060-9</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-2952 |
ispartof | Biochemical pharmacology, 1989-07, Vol.38 (13), p.2077-2086 |
issn | 0006-2952 1873-2968 |
language | eng |
recordid | cdi_proquest_miscellaneous_79046978 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Alkaloids - pharmacology Amsacrine - pharmacology Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Carcinoma, Small Cell Cell Division - drug effects Cell Line DNA - drug effects DNA Damage DNA Topoisomerases, Type II - metabolism Ellipticines - pharmacology General aspects Humans Lung Neoplasms Medical sciences Pharmacology. Drug treatments Tumor Cells, Cultured - drug effects Tumor Cells, Cultured - enzymology |
title | Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Topoisomerase%20II-mediated%20DNA%20cleavage%20activity%20induced%20by%20ellipticines%20on%20the%20human%20tumor%20cell%20line%20N417&rft.jtitle=Biochemical%20pharmacology&rft.au=Multon,%20Eric&rft.date=1989-07-01&rft.volume=38&rft.issue=13&rft.spage=2077&rft.epage=2086&rft.pages=2077-2086&rft.issn=0006-2952&rft.eissn=1873-2968&rft.coden=BCPCA6&rft_id=info:doi/10.1016/0006-2952(89)90060-9&rft_dat=%3Cproquest_cross%3E79046978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79046978&rft_id=info:pmid/2544183&rft_els_id=0006295289900609&rfr_iscdi=true |